Loading…
Arcus Biosciences, Inc. is projected to rise to $29.05 by 2027, a +21% move from its current price of $23.97. RCUS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $23.36 | $23.96 | $24.59 | -0.02% |
| May 30 | $23.11 | $23.96 | $24.85 | -0.04% |
| May 31 | $22.91 | $23.95 | $25.04 | -0.06% |
| Jun 1 | $22.75 | $23.95 | $25.21 | -0.08% |
| Jun 2 | $22.61 | $23.94 | $25.36 | -0.11% |
| Jun 3 | $22.48 | $23.94 | $25.49 | -0.13% |
| Jun 4 | $22.36 | $23.93 | $25.62 | -0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.36 | $23.93 | $25.62 | -0.15% |
| Week 2 | $21.71 | $23.90 | $26.31 | -0.29% |
| Week 3 | $21.22 | $23.86 | $26.84 | -0.44% |
| Week 4 | $20.80 | $23.83 | $27.30 | -0.59% |
| Week 5 | $20.44 | $23.79 | $27.70 | -0.74% |
| Week 6 | $20.12 | $23.76 | $28.06 | -0.88% |
| Week 7 | $19.82 | $23.72 | $28.39 | -1.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer.
In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases.
Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Arcus Biosciences, Inc. (RCUS) is currently priced at $23.43. The company has a market cap of $2.95B and is ranked 1742. The forecast outlook shows a path of growth across multiple years, with 2026 average around $23.43 and rising through 2027 ($27.67), 2028 ($29.38), 2029 ($37.94), then 2030 ($46.23) and continuing higher to 2031 ($46.77), 2032 ($51.62), 2033 ($54.63), 2034 ($55.88), and 2035 ($65.95).
The long-range outlook extends to 2040 ($96.03) and 2050 ($207.46) with notable upside reflected in the max forecasts (2030: $67.08; 2040: $161.13; 2050: $380.08).
A major floor 21.4% below — a decisive break under it would weaken the trend.
The nearest floor, 5.1% below — buyers have tended to step in here.
The nearest ceiling, 11.1% above — a clean break opens room to run.
A major ceiling 18.2% above — clearing it would confirm fresh momentum.
Key RCUS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RCUS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $23.83 | Buy | $23.87 | Buy |
| MA 10 | $23.90 | Buy | $24.00 | Sell |
| MA 20 | $24.62 | Sell | $24.18 | Sell |
| MA 50 | $23.53 | Buy | $23.70 | Buy |
| MA 100 | $22.58 | Buy | $22.58 | Buy |
| MA 200 | $19.85 | Buy | $20.28 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.90 | Neutral |
| Stoch RSI (14) | 56.47 | Neutral |
| CCI (20) | -51.64 | Neutral |
| Williams %R (14) | -53.26 | Info |
| MACD (12,26,9) | -0.18 | Sell |
| ROC (12) | -5.48 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 46.74 | Neutral |
| TRIX (15) | 0.09 | Buy |
| Awesome (5,34) | -0.56 | Sell |
| Ultimate (7,14,28) | 47.64 | Neutral |
| Momentum (10) | -0.93 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 23.91 | Buy |
| ADX (14) | 10.11 | Neutral |
| ATR (14) | 0.55 | Info |
The 30-day technical picture is bullish. RSI(14) sits at 50, with the 50-day simple moving average at $23.46 and the 200-day simple moving average at $19.70, suggesting a constructive near-term trend. Support is noted at $22.39 and resistance at $26.62, framing a near-term trading band.
The 30-day price range runs from a low of $19.66 to a high of $27.92, indicating some volatility within the current zone.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.85 | $23.97 | $31.20 | 0% | Neutral | |
| $23.17 | $29.05 | $38.49 | +21% | Bullish | |
| $24.27 | $31.20 | $42.77 | +30% | Bullish | |
| $30.66 | $40.26 | $56.69 | +68% | Bullish | |
| $37.01 | $49.53 | $71.34 | +107% | Bullish | |
| $37.17 | $50.60 | $74.35 | +111% | Bullish | |
| $40.42 | $55.91 | $83.64 | +133% | Bullish | |
| $42.64 | $59.86 | $91.02 | +150% | Bullish | |
| $43.41 | $61.81 | $95.41 | +158% | Bullish | |
| $50.59 | $73.03 | $114.30 | +205% | Bullish | |
| $70.69 | $108.53 | $180.13 | +353% | Bullish | |
| $139.25 | $237.55 | $429.66 | +891% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $18.85 | $23.97 | $28.21 | +0.00% |
| June 2026 | $20.63 | $24.19 | $29.02 | +0.92% |
| July 2026 | $19.89 | $23.51 | $28.57 | -2.80% |
| August 2026 | $19.79 | $23.54 | $28.88 | +0.10% |
| September 2026 | $20.30 | $24.27 | $30.02 | +3.13% |
| October 2026 | $20.22 | $24.29 | $30.25 | +0.06% |
| November 2026 | $19.93 | $24.04 | $30.14 | -1.02% |
| December 2026 | $20.43 | $24.74 | $31.20 | +2.91% |
Click any year to see its month-by-month RCUS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Arcus Biosciences, Inc.'s 2026 outlook centres on $23.97, within a $18.85 to $31.20 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, RCUS could reach as high as $38.49, with a base case around $29.05 and support toward $23.17 — roughly +21% from $23.97. Buyers look set to stay in control over this stretch.
Expect RCUS to range from $24.27 to $42.77 through 2028. The $31.20 average target implies a +30% move from current prices. That is up +7% on the projected 2027 average. Momentum favours further upside here.
The RCUS price prediction for 2029 points to an average of $40.26 (low $30.66, high $56.69) — a potential gain of +68% on today's $23.97. Buyers look set to stay in control over this stretch.
In 2030, RCUS is projected to trade between $37.01 and $71.34, averaging $49.53 — a potential gain of +107% from today's $23.97. That is up +23% on the projected 2029 average. Momentum favours further upside here.
Arcus Biosciences, Inc.'s 2031 outlook centres on $50.60, within a $37.17 to $74.35 range. That is up +2% on the projected 2030 average. That marks a +111% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, RCUS could reach as high as $83.64, with a base case around $55.91 and support toward $40.42 — roughly +133% from $23.97. Momentum favours further upside here.
Expect RCUS to range from $42.64 to $91.02 through 2033. The $59.86 average target implies a +150% move from current prices. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The RCUS price prediction for 2034 points to an average of $61.81 (low $43.41, high $95.41) — a potential gain of +158% on today's $23.97. Momentum favours further upside here.
In 2035, RCUS is projected to trade between $50.59 and $114.30, averaging $73.03 — a potential gain of +205% from today's $23.97. That is up +18% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Arcus Biosciences, Inc.'s 2040 outlook centres on $108.53, within a $70.69 to $180.13 range. That is up +49% on the projected 2035 average. That marks a +353% change versus current levels. Momentum favours further upside here.
By 2050, RCUS could reach as high as $429.66, with a base case around $237.55 and support toward $139.25 — roughly +891% from $23.97. Buyers look set to stay in control over this stretch.
Investing $1,000 in RCUS today (≈ 41.718815 RCUS) could be worth
$9,910.26
+$8,910.26 (+891%) by 2050 · US Dollar
Based on the average projected RCUS price of $237.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RCUSwould be worth at today's price.
$1,000 invested in RCUS on May 27, 2025 (≈ 110.741974 RCUS) would be worth
$2,654.49
+$1,654.49 (+165.4%) today · 2.65× · US Dollar
Based on a RCUS entry price of $9.03 vs. today's $23.97.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.74 | $1,009.69 | +1.0% |
| 1 month ago | $24.95 | $960.72 | -3.9% |
| 3 months ago | $19.54 | $1,226.71 | +22.7% |
| 6 months ago | $26.1 | $918.39 | -8.2% |
| 1 year ago | $9.03 | $2,654.49 | +165.4% |
| All time (5.0y) ago | $24.59 | $974.79 | -2.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RCUS forecast.
Our base-case forecast reaches $48.00 around 2030.
Implied market cap at $48.00: $6.04B
The multi-year forecast implies meaningful upside over the long horizon. By 2030, the average forecast price is $46.23 with an ROI of 97.3%, and the sentiment remains bullish. By 2040, the average forecast price is $96.03 with an ROI of 309.9%.
By 2050, the average forecast price is $207.46 with an ROI of 785.4%. These trajectories point to substantial increases from current levels, albeit as estimates rather than guarantees. Max forecast values illustrate upside potential: 2030 max $67.08, 2040 max $161.13, 2050 max $380.08.
Tap a question to reveal the answer.
In 2030, the average forecast price is $46.23 with an ROI of 97.3%.
The 2027 forecast shows an average of $27.67 and a max of $36.85, with an ROI of 18.1%.
For 2040, the average forecast price is $96.03 with a max of $161.13 and an ROI of 309.9%.
The current price is $23.43. The 30-day range runs from $19.66 to $27.92.
In 2050, the average forecast price is $207.46 with a max of $380.08 and an ROI of 785.4%.
Arcus Biosciences, Inc. Community Discussion
0Share your Arcus Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.